Nuclear medicine in NET

Summary Neuroendocrine tumors (NET) are, despite increasing incidence, still rare, usually slow growing neoplasms with resemblance to nerve cells and the endocrine capability of hormone production. In contrast to commonly used conventional imaging procedures, nuclear imaging is feasible to visualize...

Full description

Saved in:
Bibliographic Details
Published in:Wiener medizinische Wochenschrift 2012-10, Vol.162 (19-20), p.416-422
Main Authors: Sorschag, Manfred, Malle, Phillip, Gallowitsch, Hans-Jürgen
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Cell Proliferation
Dihydroxyphenylalanine - analogs & derivatives
Family Medicine
Fluorodeoxyglucose F18
Gallium Radioisotopes
General Practice
Geriatrics/Gerontology
Humans
Infectious Diseases
Internal Medicine
Main Topic
Medicine
Medicine & Public Health
Multimodal Imaging - methods
Neoplasm Staging
Neuroendocrine Tumors - diagnostic imaging
Neuroendocrine Tumors - pathology
Neuroendocrine Tumors - radiotherapy
Pharmacology/Toxicology
Positron-Emission Tomography - methods
Prognosis
Radionuclide Imaging - methods
Receptors, Peptide - analysis
Receptors, Somatostatin - analysis
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Neuroendocrine tumors (NET) are, despite increasing incidence, still rare, usually slow growing neoplasms with resemblance to nerve cells and the endocrine capability of hormone production. In contrast to commonly used conventional imaging procedures, nuclear imaging is feasible to visualize the presence of molecular biomarkers, particularly the overexpression of somatostatin receptors (sstr) with high diagnostic accuracy which has led to the establishment of somatostatin receptor scintigraphy (SRS) as essential component and gold standard of functional imaging in the workup of NET. Another major feature is the selection of patients with inoperable or metastasized tumors showing sufficient uptake for peptide receptor radionuclide therapy (PRRT). While somatostatin receptor PET and PET/CT using Ga-68-labeled SSR analogs represents the consistent further development of SRS, FDG-PET can only be used in tumors with high proliferative activity but not on a routine basis for imaging of neuroendocrine tumors. 18 F-DOPA represents an alternative PET tracer worth mentioning currently under assessment for NET imaging.
ISSN:0043-5341
1563-258X
DOI:10.1007/s10354-012-0130-z